In comparison with noncarriers, AD patient carriers of the ε4 allele typically have low CSF Aβ42 and elevated CSF levels of P-tau and T-tau, along with accelerated atrophy patterns on MRI. The gene discussed is MAPT; the disease is Alzheimer disease.